U.S. Markets close in 5 hrs 14 mins

Anixa Biosciences, Inc. (ANIX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.6400-0.0100 (-0.22%)
As of 10:43AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.6500
Open4.6900
Bid4.6100 x 900
Ask4.6600 x 1000
Day's Range4.6000 - 4.7500
52 Week Range1.6500 - 8.0900
Volume71,653
Avg. Volume655,316
Market Cap125.89M
Beta (5Y Monthly)1.45
PE Ratio (TTM)N/A
EPS (TTM)-0.4130
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.50
  • Anixa Biosciences and OntoChem Enter Next Stage of Development for Covid-19 Therapeutic
    PR Newswire

    Anixa Biosciences and OntoChem Enter Next Stage of Development for Covid-19 Therapeutic

    Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that based on Proof of Concept (POC) animal study results, it will progress to the next stage of development of its potential anti-viral therapy for Covid-19.

  • Anixa Biosciences Increases Previously Announced Bought Deal Offering of Common Stock to $22.5 Million
    PR Newswire

    Anixa Biosciences Increases Previously Announced Bought Deal Offering of Common Stock to $22.5 Million

    Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa" or the "Company"), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that, due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 4,285,715 shares of common stock of the Company at a public offering price of $5.25 per share, less underwriting discounts and commissions. The Company also has granted the underwriter a 30-day option to purchase up to an additional 642,857 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about March 25, 2021, subject to satisfaction of customary closing conditions.

  • Anixa Biosciences Announces $10 Million Bought Deal Offering of Common Stock
    PR Newswire

    Anixa Biosciences Announces $10 Million Bought Deal Offering of Common Stock

    Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa" or the "Company"), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co. under which the underwriter has agreed to purchase on a firm commitment basis 1,904,762 shares of common stock of the Company at a public offering price of $5.25 per share, less underwriting discounts and commissions. The Company also has granted the underwriter a 30-day option to purchase up to an additional 285,714 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about March 25, 2021, subject to satisfaction of customary closing conditions.